Alphavirus antiviral drug development: Scientific gap analysis and prospective research areas

Erin Reichert, Amanda Clase, Ada Bacetty, Joseph Larsen

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The New World alphaviruses Venezuelan equine encephalitis virus (VEEV), eastern equine encephalitis virus (EEEV), and western equine encephalitis virus (WEEV) pose a significant threat to human health as the etiological agents of serious viral encephalitis through natural infection as well as through their potential use as a biological weapon. At present, there is no FDA-approved medical treatment for infection with these viruses. The Defense Threat Reduction Agency, Joint Science and Technology Office for Chemical and Biological Defense (DTRA/JSTO), is currently funding research aimed at developing antiviral drugs and vaccines against VEEV, EEEV, and WEEV. A review of antiviral drug discovery efforts for these viruses revealed significant gaps in the data, assays, and models required for successful drug development. This review provides a description of these gaps and highlights specific critical research areas for the development of a target-based drug discovery program for the VEEV, EEEV, and WEEV nonstructural proteins. These efforts will increase the probability of the successful development of a pharmaceutical intervention against these viral threat agents. 2009

Original languageEnglish (US)
Pages (from-to)413-427
Number of pages15
JournalBiosecurity and Bioterrorism
Volume7
Issue number4
DOIs
StatePublished - Dec 1 2009

Fingerprint

Western Equine Encephalitis Viruses
Eastern equine encephalitis virus
Venezuelan Equine Encephalitis Viruses
drug development
Alphavirus
encephalitis
Viruses
Antiviral Agents
virus
Drug Discovery
drug
threat
Biological Warfare Agents
Research
Viral Encephalitis
office technology
Virus Diseases
biological weapon
Pharmaceutical Preparations
Vaccines

All Science Journal Classification (ASJC) codes

  • Health(social science)
  • Public Health, Environmental and Occupational Health
  • Management, Monitoring, Policy and Law

Cite this

Reichert, Erin ; Clase, Amanda ; Bacetty, Ada ; Larsen, Joseph. / Alphavirus antiviral drug development : Scientific gap analysis and prospective research areas. In: Biosecurity and Bioterrorism. 2009 ; Vol. 7, No. 4. pp. 413-427.
@article{281f5b344c2144a6b088bf10faa8cbba,
title = "Alphavirus antiviral drug development: Scientific gap analysis and prospective research areas",
abstract = "The New World alphaviruses Venezuelan equine encephalitis virus (VEEV), eastern equine encephalitis virus (EEEV), and western equine encephalitis virus (WEEV) pose a significant threat to human health as the etiological agents of serious viral encephalitis through natural infection as well as through their potential use as a biological weapon. At present, there is no FDA-approved medical treatment for infection with these viruses. The Defense Threat Reduction Agency, Joint Science and Technology Office for Chemical and Biological Defense (DTRA/JSTO), is currently funding research aimed at developing antiviral drugs and vaccines against VEEV, EEEV, and WEEV. A review of antiviral drug discovery efforts for these viruses revealed significant gaps in the data, assays, and models required for successful drug development. This review provides a description of these gaps and highlights specific critical research areas for the development of a target-based drug discovery program for the VEEV, EEEV, and WEEV nonstructural proteins. These efforts will increase the probability of the successful development of a pharmaceutical intervention against these viral threat agents. 2009",
author = "Erin Reichert and Amanda Clase and Ada Bacetty and Joseph Larsen",
year = "2009",
month = "12",
day = "1",
doi = "10.1089/bsp.2009.0032",
language = "English (US)",
volume = "7",
pages = "413--427",
journal = "Health security",
issn = "2326-5094",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

Alphavirus antiviral drug development : Scientific gap analysis and prospective research areas. / Reichert, Erin; Clase, Amanda; Bacetty, Ada; Larsen, Joseph.

In: Biosecurity and Bioterrorism, Vol. 7, No. 4, 01.12.2009, p. 413-427.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Alphavirus antiviral drug development

T2 - Scientific gap analysis and prospective research areas

AU - Reichert, Erin

AU - Clase, Amanda

AU - Bacetty, Ada

AU - Larsen, Joseph

PY - 2009/12/1

Y1 - 2009/12/1

N2 - The New World alphaviruses Venezuelan equine encephalitis virus (VEEV), eastern equine encephalitis virus (EEEV), and western equine encephalitis virus (WEEV) pose a significant threat to human health as the etiological agents of serious viral encephalitis through natural infection as well as through their potential use as a biological weapon. At present, there is no FDA-approved medical treatment for infection with these viruses. The Defense Threat Reduction Agency, Joint Science and Technology Office for Chemical and Biological Defense (DTRA/JSTO), is currently funding research aimed at developing antiviral drugs and vaccines against VEEV, EEEV, and WEEV. A review of antiviral drug discovery efforts for these viruses revealed significant gaps in the data, assays, and models required for successful drug development. This review provides a description of these gaps and highlights specific critical research areas for the development of a target-based drug discovery program for the VEEV, EEEV, and WEEV nonstructural proteins. These efforts will increase the probability of the successful development of a pharmaceutical intervention against these viral threat agents. 2009

AB - The New World alphaviruses Venezuelan equine encephalitis virus (VEEV), eastern equine encephalitis virus (EEEV), and western equine encephalitis virus (WEEV) pose a significant threat to human health as the etiological agents of serious viral encephalitis through natural infection as well as through their potential use as a biological weapon. At present, there is no FDA-approved medical treatment for infection with these viruses. The Defense Threat Reduction Agency, Joint Science and Technology Office for Chemical and Biological Defense (DTRA/JSTO), is currently funding research aimed at developing antiviral drugs and vaccines against VEEV, EEEV, and WEEV. A review of antiviral drug discovery efforts for these viruses revealed significant gaps in the data, assays, and models required for successful drug development. This review provides a description of these gaps and highlights specific critical research areas for the development of a target-based drug discovery program for the VEEV, EEEV, and WEEV nonstructural proteins. These efforts will increase the probability of the successful development of a pharmaceutical intervention against these viral threat agents. 2009

UR - http://www.scopus.com/inward/record.url?scp=77749283581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749283581&partnerID=8YFLogxK

U2 - 10.1089/bsp.2009.0032

DO - 10.1089/bsp.2009.0032

M3 - Article

C2 - 20028250

AN - SCOPUS:77749283581

VL - 7

SP - 413

EP - 427

JO - Health security

JF - Health security

SN - 2326-5094

IS - 4

ER -